Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma
Mohamed A. Gouda(The University of Texas MD Anderson Cancer Center), Filip Jankú(The University of Texas MD Anderson Cancer Center), Kristýna Pivovarčíková(Charles University), T. Fikrle, Jiří Polívka(Charles University), S. Greg Call(The University of Texas MD Anderson Cancer Center), Martin Pešta(Charles University), Derek Dustin(Baylor College of Medicine), Hong Huang(Suzhou Guangji Hospital), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), V. Woznica
Cited by 26
Related Papers
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
|Blood|2016|1.6k
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
|Journal of Clinical Oncology|2023|882
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
|The Lancet Oncology|2019|564
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530